Veravas Launches VeraBIND Tau to Detect Alzheimer's Disease & other Tauopathies
Shots:
- Veravas has launched VeraBIND Tau to detect both symptomatic & pre-symptomatic pts with Alzheimer's disease (AD) or other tau-related neurodegenerative disorders (tauopathies)
- In an analytical verification study, VeraBIND Tau showed 96% sensitivity, 90% specificity, & 92% agreement with tau PET imaging, detecting Alzheimer’s-related tau & offering VeraBIND Tau score, a semi-quantitative measure of pathologically active tau
- VeraBIND Tau is a validated blood-based test that utilizes VeraBIND platform to isolate & measure hyperphosphorylated tau in blood, allowing early identification of Alzheimer’s risk even in cognitively normal individuals
Ref: Prnewswire | Image: Veravas
Related News:- Novocure Reports CE Mark Approval of Optune Lua for Metastatic NSCLC (mNSCLC)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Ridhi is an avid secondary researcher who follows trends in the biopharmaceutical and healthcare sectors to curate engaging content for the global audience. She works as a news editor at PharmaShots and loves to read books and explore new destinations.
